Emergent BioSolutions (STU:ER4) Short Interest


STU:ER4 Emergent BioSolutions Inc STU:ER4
57 GF Score
Price €7.34
GF Value €4.05
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Emergent BioSolutions Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

STU:ER4 vs AQST, EOLS, ELTP: Short Interest Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Emergent BioSolutions's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Emergent BioSolutions Short Interest vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Emergent BioSolutions's Short Interest distribution charts can be found below:

* The bar in red indicates where Emergent BioSolutions's Short Interest falls into.


STU:ER4
57GF Score
Emergent BioSolutions Inc STU:ER4
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Emergent BioSolutions (STU:ER4) Overvalued in 2026?

Based on GuruFocus' analysis, Emergent BioSolutions stock appears to be overvalued. The current stock price of €7.34 is trading 81.1% above its estimated GF Value™ of €4.05. GuruFocus considers Emergent BioSolutions to be Significantly Overvalued.

Key valuation signals for STU:ER4:

  • Short Interest:
  • GF Value™: €4.05 vs. price of €7.34 (81.1% above fair value)
  • GF Score™: 57/100 with 5 warning signs

No single metric tells the full story. See the STU:ER4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Emergent BioSolutions Business Description

Other Exchanges EBS:USA0IGA:UK
Address 300 Professional Drive, Gaithersburg, MD, USA, 20879
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
57GF Score

Get the complete analysis for STU:ER4

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.34
Price
€4.05
GF Value